52 articles for X Tian
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery and Pre-Clinical Characterization of Third-Generation 4-H Heteroaryldihydropyrimidine (HAP) Analogues as Hepatitis B Virus (HBV) Capsid Inhibitors.
Roche Innovation Center Shanghai
An overview of the binding models of FGFR tyrosine kinases in complex with small molecule inhibitors.
The First Affiliated Hospital of Zhengzhou University
Synthesis and biological evaluation of open-chain analogs of cyclic peptides as inhibitors of cellular Shp2 activity.
Hebei University of Science & Technology
Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2.
TBA
Design, synthesis, and evaluation of proline based melanocortin receptor ligands.
Procter & Gamble Pharmaceuticals
Synthesis and pharmacological evaluation of 3-(3,4-dichlorophenyl)-1-indanamine derivatives as nonselective ligands for biogenic amine transporters.
National Institute of Diabetes and Digestive and Kidney Diseases
Antagonism of 4-substituted 1,4-dihydropyridine-3,5-dicarboxylates toward voltage-dependent L-type Ca2+ channels Ca V 1.3 and Ca V 1.2.
Northwestern University
Efficacious 11beta-hydroxysteroid dehydrogenase type I inhibitors in the diet-induced obesity mouse model.
Wyeth Research
Discovery of orally bioavailable 1,3,4-trisubstituted 2-oxopiperazine-based melanocortin-4 receptor agonists as potential antiobesity agents.
Procter & Gamble Pharmaceuticals
A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC.
Johns Hopkins University
Lipid-conjugated nucleoside monophosphate and monophosphonate prodrugs: A versatile drug delivery paradigm.
Xichang University
Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity.
Northeastern University
Discovery of first-in-class highly selective TRPV1 antagonists with dual analgesic and hypoglycemic effects.
The First Affiliated Hospital of Zhengzhou University
Discovery and preclinical evaluations of TQB3616, a novel CDK4-biased inhibitor.
WuXi AppTec
Research progress and challenges of TRPV1 channel modulators as a prospective therapy for diabetic neuropathic pain.
The First Affiliated Hospital of Zhengzhou University
Advances in Epilepsy: Mechanisms, Clinical Trials, and Drug Therapies.
Sichuan University
Structure-Activity Relationship of Novel Pyrimidine Derivatives with Potent Inhibitory Activities against
Sichuan University
Selective Covalent Targeting of Pyruvate Kinase M2 Using Arsenous Warheads.
Chinese Academy of Sciences
Design, synthesis and biological evaluation of 2,4,6- trisubstituted triazine derivatives as new nonpeptide small-molecule SIRT5 inhibitors.
Xihua University
Discovery of Linvencorvir (RG7907), a Hepatitis B Virus Core Protein Allosteric Modulator, for the Treatment of Chronic HBV Infection.
China Innovation Center of Roche
Design, synthesis, and evaluation of proline and pyrrolidine based melanocortin receptor agonists. A conformationally restricted dipeptide mimic approach.
Procter & Gamble Pharmaceuticals
Discovery of Proline-Based p300/CBP Inhibitors Using DNA-Encoded Library Technology in Combination with High-Throughput Screening.
Glaxosmithkline
Design and synthesis of potent and selective 1,3,4-trisubstituted-2-oxopiperazine based melanocortin-4 receptor agonists.
Procter & Gamble Pharmaceuticals
Synthesis of Tic-D-Phe Psi[CH2-CH2] isostere and its use in the development of melanocortin receptor agonists.
Procter & Gamble Pharmaceuticals
Hematopoietic Progenitor Kinase 1 in Tumor Immunology: A Medicinal Chemistry Perspective.
China Pharmaceutical University
Dentithecamides A-H, Diacylated Zoanthoxanthin Derivatives with PAX3-FOXO1 Inhibitory Activity from the Hydroid
Yangzhou University
Rational Design, Synthesis, and Biological Evaluation of Novel S1PR2 Antagonists for Reversing 5-FU-Resistance in Colorectal Cancer.
Ocean University of China
Unique Oxidative Metabolism of Bufalin Generates Two Reactive Metabolites That Strongly Inactivate Human Cytochrome P450 3A.
Shanghai University of Traditional Chinese Medicine
Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer.
Laboratory For Marine Drugs and Bioproducts of Qingdao National Laboratory For Marine Science and Technology
Discovery of LYC-55716: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor-γ (RORγ) Agonist for Use in Treating Cancer.
Lycera
Axial Chiral Binaphthoquinone and Perylenequinones from the Stromata of
Chinese Academy of Sciences
Novel irreversible covalent BTK inhibitors discovered using DNA-encoded chemistry.
X-Chem
Machine Learning on DNA-Encoded Libraries: A New Paradigm for Hit Finding.
Google Research Applied Science, Mountain View, California 94043, United States.
The development of a potential single photon emission computed tomography (SPECT) imaging agent for the corticotropin-releasing hormone receptor type.
Niddk
Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures.
The First Affiliated Hospital of Zhengzhou University
Small-Molecule Antagonist Targeting Exportin-1 via Rational Structure-Based Discovery.
Dalian University of Technology
Novel conformationally restricted tetracyclic analogs of delta8-tetrahydrocannabinol.
University of Connecticut
Structure-activity relationship study of a series of caspase inhibitors containing γ-amino acid moiety for treatment of cholestatic liver disease.
Wuxi Apptec (Shanghai)
Discovery of Potent EV71 Capsid Inhibitors for Treatment of HFMD.
Wuxi Apptec (Shanghai)
Synthesis and Biological Evaluation of a Series of Bile Acid Derivatives as FXR Agonists for Treatment of NASH.
Wuxi Apptec (Shanghai)
SUBSTITUTED HYDANTOIN COMPOUNDS, METHODS FOR PREPARATION THEREOF AND USE THEREOF IN THE TREATMENT AND/OR PREVENTION OF A CORONA VIRUS DISEASE
Individual
Compounds as neuronal histamine receptor-3 antagonists and uses thereof
Xw Laboratories
Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
Bristol-Myers Squibb